
Novo Nordisk A/S
CSE:NOVO B

Novo Nordisk A/S?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
390
1 028
|
Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Novo Nordisk A/S hold over its rivals?
What risks and challenges
does Novo Nordisk A/S face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Novo Nordisk A/S.
Provide an overview of the primary business activities
of Novo Nordisk A/S.
What unique competitive advantages
does Novo Nordisk A/S hold over its rivals?
What risks and challenges
does Novo Nordisk A/S face in the near future?
Summarize the latest earnings call
of Novo Nordisk A/S.
What significant events have occurred
in Novo Nordisk A/S over the past months?
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Novo Nordisk A/S.
Provide P/S
for Novo Nordisk A/S.
Provide P/E
for Novo Nordisk A/S.
Provide P/OCF
for Novo Nordisk A/S.
Provide P/FCFE
for Novo Nordisk A/S.
Provide P/B
for Novo Nordisk A/S.
Provide EV/S
for Novo Nordisk A/S.
Provide EV/GP
for Novo Nordisk A/S.
Provide EV/EBITDA
for Novo Nordisk A/S.
Provide EV/EBIT
for Novo Nordisk A/S.
Provide EV/OCF
for Novo Nordisk A/S.
Provide EV/FCFF
for Novo Nordisk A/S.
Provide EV/IC
for Novo Nordisk A/S.
Show me price targets
for Novo Nordisk A/S made by professional analysts.
What are the Revenue projections
for Novo Nordisk A/S?
How accurate were the past Revenue estimates
for Novo Nordisk A/S?
What are the Net Income projections
for Novo Nordisk A/S?
How accurate were the past Net Income estimates
for Novo Nordisk A/S?
What are the EPS projections
for Novo Nordisk A/S?
How accurate were the past EPS estimates
for Novo Nordisk A/S?
What are the EBIT projections
for Novo Nordisk A/S?
How accurate were the past EBIT estimates
for Novo Nordisk A/S?
Compare the revenue forecasts
for Novo Nordisk A/S with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Novo Nordisk A/S and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Novo Nordisk A/S against its competitors.
Analyze the profit margins
(gross, operating, and net) of Novo Nordisk A/S compared to its peers.
Compare the P/E ratios
of Novo Nordisk A/S against its peers.
Discuss the investment returns and shareholder value creation
comparing Novo Nordisk A/S with its peers.
Analyze the financial leverage
of Novo Nordisk A/S compared to its main competitors.
Show all profitability ratios
for Novo Nordisk A/S.
Provide ROE
for Novo Nordisk A/S.
Provide ROA
for Novo Nordisk A/S.
Provide ROIC
for Novo Nordisk A/S.
Provide ROCE
for Novo Nordisk A/S.
Provide Gross Margin
for Novo Nordisk A/S.
Provide Operating Margin
for Novo Nordisk A/S.
Provide Net Margin
for Novo Nordisk A/S.
Provide FCF Margin
for Novo Nordisk A/S.
Show all solvency ratios
for Novo Nordisk A/S.
Provide D/E Ratio
for Novo Nordisk A/S.
Provide D/A Ratio
for Novo Nordisk A/S.
Provide Interest Coverage Ratio
for Novo Nordisk A/S.
Provide Altman Z-Score Ratio
for Novo Nordisk A/S.
Provide Quick Ratio
for Novo Nordisk A/S.
Provide Current Ratio
for Novo Nordisk A/S.
Provide Cash Ratio
for Novo Nordisk A/S.
What is the historical Revenue growth
over the last 5 years for Novo Nordisk A/S?
What is the historical Net Income growth
over the last 5 years for Novo Nordisk A/S?
What is the current Free Cash Flow
of Novo Nordisk A/S?
Discuss the annual earnings per share (EPS)
trend over the past five years for Novo Nordisk A/S.
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK | 12.9 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
678.1B USD | 32.9 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
364.9B USD | 12.2 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
205.8B CHF | 9.3 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
181.3B CHF | 10.1 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
160.7B GBP | 130.6 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
193.3B USD | 8.3 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD | 261.3 |
|
FR |
![]() |
Sanofi SA
PAR:SAN
|
116.8B EUR | 5.1 |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
129.8B USD | 7.2 |
|
EBITDA Growth | EV/EBITDA to Growth | |||||
---|---|---|---|---|---|---|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
Average EV/EBITDA:
394.2
12.9
|
14%
|
0.9 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
32.9
|
31%
|
1.1 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
3 846.3
|
36%
|
106.8 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
12.2
|
8%
|
1.5 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
9.3
|
6%
|
1.6 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
10.1
|
5%
|
2 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
130.6
|
9%
|
14.5 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
8.3
|
9%
|
0.9 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
261.3
|
N/A | N/A |
|
FR |
![]() |
Sanofi SA
PAR:SAN
|
5.1
|
8%
|
0.6 |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
7.2
|
2%
|
3.6 |
|
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.